FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011304249> ?p ?o ?g. }

• W2011304249 endingPage "777" @default.
• W2011304249 startingPage "767" @default.
• W2011304249 abstract "Considerable evidence links urokinase plasminogen activator (uPA) bound to its surface receptor (uPAR) with enhanced invasiveness of cancer cells. By blocking uPAR expression in human epidermoid carcinoma cells (HEp3), we have now identified an additional and novel in vivo function for this receptor by showing that receptor-deficient cells enter a state of dormancy reminiscent of that observed in human cancer metastasis. Its main characteristic is survival without signs of progressive growth. Five clones transfected with a vector expressing uPAR antisense RNA under the β-actin promoter were isolated and shown to have uPAR (at the mRNA and protein levels) reduced by 50 to 80%; four clones, transfected with vector alone and having uPAR levels similar to those of parental cells, served as controls. In confirmation of our previous results, reduced uPAR always coincided with a significantly reduced invasiveness. Each of the control clones produced rapidly growing, highly metastatic tumors within 2 wk of inoculation on chorioallantoic membranes (CAMs) of chick embryos. In contrast, each of the clones with low surface uPAR, whose proliferation rate in culture was indistinguishable from controls, remained dormant for up to 5 mo when inoculated on CAMs. Thus, the reduction in uPAR altered the phenotype of HEp3 tumor cells from tumorigenic to dormant. Although protracted, tumor dormancy was not permanent since in spite of maintaining low uPAR levels, each of the in vivo–passaged antisense clones eventually reemerged from dormancy to initiate progressive growth and to form metastases at a level of 20 to 90% of that of fully malignant control. This observation suggested that other factors, whose expression is dependent on cumulative and prolonged in vivo effects, can compensate for the lack of a full complement of surface uPAR required for the expression of malignant properties. These “reemerged,” uPAR-deficient clones were easily distinguishable from the vector-transfected controls by the fact that after only 1 wk in culture, the invasion of CAM by all five clones and tumorigenicity of four of the five clones were reduced back to the values observed before in vivo maintenance. In contrast, dissociated and in vitro–grown cells of control tumors were fully invasive and produced large, metastatic tumors when reinoculated on CAMs. Quantitation of the percent of apoptotic and S-phase cells in vivo, in the control and uPAR-deficient, dormant clones, showed that the mechanism responsible for the dormancy was a diminished proliferation." @default.
• W2011304249 created "2016-06-24" @default.
• W2011304249 creator A5037433877 @default.
• W2011304249 creator A5041082380 @default.
• W2011304249 creator A5079263087 @default.
• W2011304249 date "1997-05-05" @default.
• W2011304249 modified "2023-10-13" @default.
• W2011304249 title "Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy" @default.
• W2011304249 cites W1275325292 @default.
• W2011304249 cites W1530528508 @default.
• W2011304249 cites W1552642838 @default.
• W2011304249 cites W1553385403 @default.
• W2011304249 cites W1559797510 @default.
• W2011304249 cites W1579642535 @default.
• W2011304249 cites W1604744894 @default.
• W2011304249 cites W1607036748 @default.
• W2011304249 cites W1670027677 @default.
• W2011304249 cites W1672973700 @default.
• W2011304249 cites W1794257889 @default.
• W2011304249 cites W1822987370 @default.
• W2011304249 cites W1853643611 @default.
• W2011304249 cites W1949259756 @default.
• W2011304249 cites W1979302845 @default.
• W2011304249 cites W1980839772 @default.
• W2011304249 cites W1984533079 @default.
• W2011304249 cites W1995142571 @default.
• W2011304249 cites W1997375815 @default.
• W2011304249 cites W1997526503 @default.
• W2011304249 cites W2000723452 @default.
• W2011304249 cites W2009240587 @default.
• W2011304249 cites W2018906560 @default.
• W2011304249 cites W2024231269 @default.
• W2011304249 cites W2032484868 @default.
• W2011304249 cites W2048581480 @default.
• W2011304249 cites W2049631846 @default.
• W2011304249 cites W2055114143 @default.
• W2011304249 cites W205532431 @default.
• W2011304249 cites W2056274413 @default.
• W2011304249 cites W2068922572 @default.
• W2011304249 cites W2081969062 @default.
• W2011304249 cites W2088738897 @default.
• W2011304249 cites W2089559330 @default.
• W2011304249 cites W2100918981 @default.
• W2011304249 cites W2108148222 @default.
• W2011304249 cites W2114656038 @default.
• W2011304249 cites W2121141343 @default.
• W2011304249 cites W2121799544 @default.
• W2011304249 cites W2124325733 @default.
• W2011304249 cites W2125190135 @default.
• W2011304249 cites W2125311110 @default.
• W2011304249 cites W2129648473 @default.
• W2011304249 cites W2143067833 @default.
• W2011304249 cites W2152246048 @default.
• W2011304249 cites W2154671319 @default.
• W2011304249 cites W23122061 @default.
• W2011304249 cites W2314503228 @default.
• W2011304249 cites W2410482883 @default.
• W2011304249 cites W4243472019 @default.
• W2011304249 doi "https://doi.org/10.1083/jcb.137.3.767" @default.
• W2011304249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2139877" @default.
• W2011304249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9151680" @default.
• W2011304249 hasPublicationYear "1997" @default.
• W2011304249 type Work @default.
• W2011304249 sameAs 2011304249 @default.
• W2011304249 citedByCount "150" @default.
• W2011304249 countsByYear W20113042492012 @default.
• W2011304249 countsByYear W20113042492013 @default.
• W2011304249 countsByYear W20113042492014 @default.
• W2011304249 countsByYear W20113042492015 @default.
• W2011304249 countsByYear W20113042492016 @default.
• W2011304249 countsByYear W20113042492017 @default.
• W2011304249 countsByYear W20113042492018 @default.
• W2011304249 countsByYear W20113042492021 @default.
• W2011304249 crossrefType "journal-article" @default.
• W2011304249 hasAuthorship W2011304249A5037433877 @default.
• W2011304249 hasAuthorship W2011304249A5041082380 @default.
• W2011304249 hasAuthorship W2011304249A5079263087 @default.
• W2011304249 hasBestOaLocation W20113042491 @default.
• W2011304249 hasConcept C121608353 @default.
• W2011304249 hasConcept C1491633281 @default.
• W2011304249 hasConcept C153911025 @default.
• W2011304249 hasConcept C170493617 @default.
• W2011304249 hasConcept C207001950 @default.
• W2011304249 hasConcept C2779013556 @default.
• W2011304249 hasConcept C502942594 @default.
• W2011304249 hasConcept C54009773 @default.
• W2011304249 hasConcept C54355233 @default.
• W2011304249 hasConcept C56219504 @default.
• W2011304249 hasConcept C81885089 @default.
• W2011304249 hasConcept C86803240 @default.
• W2011304249 hasConcept C95444343 @default.
• W2011304249 hasConcept C96232424 @default.
• W2011304249 hasConceptScore W2011304249C121608353 @default.
• W2011304249 hasConceptScore W2011304249C1491633281 @default.
• W2011304249 hasConceptScore W2011304249C153911025 @default.
• W2011304249 hasConceptScore W2011304249C170493617 @default.
• W2011304249 hasConceptScore W2011304249C207001950 @default.
• W2011304249 hasConceptScore W2011304249C2779013556 @default.

• next